1.Clinicopathologic Characteristics and Therapeutic Outcomes of Primary Gastrointestinal Non-Hodgkin's Lymphomas in Central Anatolia, in Turkey.
Bulent ESER ; Bunyamin KAPLAN ; Ali UNAL ; Ozlem CANOZ ; Fevzi ALTUNTAS ; H Ismail SARI ; Ozlem ER ; Metin OZKAN ; Can KUCUK ; Makbule ARAR ; Sebnem GURSOY ; Mustafa CETIN
Yonsei Medical Journal 2006;47(1):22-33
Primary gastrointestinal lymphoma is a common presentation of non-Hodgkin's lymphoma. The main controversy arises when many aspects of its classification and management are under discussion, particularly regarding roles for surgical resection. The aim of this study was to evaluate clinicopathologic characteristics and the therapeutic outcome of primary gastrointestinal non-Hodgkin's lymphoma. We carried out a retrospective analysis of 74 patients who were presented to our center with histopathological diagnosis of primary gastro-intestinal non-Hodgkin's lymphoma between 1990 and 2001. All patients have been staged according to Lugano Staging System. For histopathological classification, International Working Formulation was applied. The treatment choice concerning the surgical or non-surgical management was decided by the initially acting physician. Treatment modalities were compared using the parameters of age, sex, histopathological results, stage, and the site of disease. Of the 74 patients, 31 were female and 43 were male, with a median age of 49 years (range 15-80). The stomach was the most common primary site and was seen in 51 of 74 patients (68.9%). The intermediate and high grade lymphomas constituted 91.9% of the all cases. In a median follow-up of 29 months (range 2-128), 20 out of 74 patients died. There was a three year overall survival rate in 65.4% of all patients. The three year overall survival rate was better in stage I and II1 patients who were treated with surgery plus chemotherapy (+/-RT) than those treated with chemotherapy alone (93.7% vs. 55.6%, p<0.05). The stage and presence of B symptoms affected the disease free survival and overall survival significantly, but the histopathologic grade only affected the overall survival. On the basis of these results, we suggest that surgical resection is necessary before chemotherapy in early stage (stage I and II1) patients with gastrointestinal non-Hodgkin's lymphomas because of the significant survival advantage it would bring to the patient.
Turkey/epidemiology
;
Treatment Outcome
;
Survival Rate
;
Retrospective Studies
;
Neoplasm Staging
;
Middle Aged
;
Male
;
Lymphoma, Non-Hodgkin/mortality/*pathology/*therapy
;
Humans
;
Gastrointestinal Diseases/mortality/*pathology/*therapy
;
Female
;
Combined Modality Therapy/adverse effects
;
Aged, 80 and over
;
Aged
;
Adult
;
Adolescent
2.Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience.
A Young LIM ; Ji Hyeon LEE ; Ki Sun JUNG ; Hye Bin GWAG ; Do Hee KIM ; Seok Jin KIM ; Ga Yeon LEE ; Jung Sun KIM ; Hee Jin KIM ; Soo Youn LEE ; Jung Eun LEE ; Eun Seok JEON ; Kihyun KIM
The Korean Journal of Internal Medicine 2015;30(4):496-505
BACKGROUND/AIMS: The gastrointestinal (GI) tract often becomes involved in patients with systemic amyloidosis. As few GI amyloidosis data have been reported, we describe the clinical features and outcomes of patients with pathologically proven GI amyloidosis. METHODS: We identified 155 patients diagnosed with systemic amyloidosis between April 1995 and April 2013. Twenty-four patients (15.5%) were diagnosed with GI amyloidosis using associated symptoms, and the diagnoses were confirmed by direct biopsy. RESULTS: Among the 24 patients, 20 (83.3%) had amyloidosis light chain (AL), three (12.5%) had amyloid A, and one (4.2%) had transthyretin-related type amyloidosis. Their median age was 57 years (range, 37 to 72), and 10 patients were female (41.7%). The most common symptoms of GI amyloidosis were diarrhea (11 patients, 45.8%), followed by anorexia (nine patients, 37.5%), weight loss, and nausea and/or vomiting (seven patients, 29.2%). The histologically confirmed GI tract site in AL amyloidosis was the stomach in 11 patients (55.0%), the colon in nine (45.0%), the rectum in seven (35.0%), and the small bowel in one (5.0%). Patients with GI involvement had a greater frequency of organ involvement (p = 0.014). Median overall survival (OS) in patients with GI involvement was shorter (7.95 months; range, 0.3 to 40.54) than in those without GI involvement (15.84 months; range, 0.0 to 114.53; p = 0.069) in a univariate analysis. A multivariate analysis of prognostic factors for AL amyloidosis revealed that GI involvement was not a significant predictor of OS (p = 0.447). CONCLUSIONS: The prognosis of patients with AL amyloidosis and GI involvement was poorer than those without GI involvement, and they presented with more organ involvement and more advanced disease than those without organ involvement.
Adult
;
Aged
;
Amyloid Neuropathies, Familial/*diagnosis/immunology/mortality/pathology/therapy
;
Biomarkers/analysis
;
Biopsy
;
Female
;
Gastrointestinal Diseases/*diagnosis/immunology/mortality/pathology/therapy
;
Gastrointestinal Tract/immunology/*pathology
;
Humans
;
Immunoglobulin Heavy Chains/analysis
;
Immunoglobulin Light Chains/analysis
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Predictive Value of Tests
;
Prognosis
;
Proportional Hazards Models
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Serum Amyloid A Protein/analysis
;
Time Factors
3.Changes in Upper Gastrointestinal Diseases according to Improvement of Helicobacter pylori Prevalence Rate in Korea.
The Korean Journal of Gastroenterology 2015;65(4):199-204
Helicobacter pylori can cause variety of upper gastrointestinal disorders such as peptic ulcer, mucosa associated lymphoid tissue (MALT)-lymphoma, and gastric cancer. The prevalence of H. pylori infection has significantly decreased in Korea since 1998 owing to active eradication of H. pylori. Along with its decrease, the prevalence of peptic ulcer has also decreased. However, the mean age of gastric ulcer increased and this is considered to be due to increase in NSAID prescription. Gastric cancer is one of the leading causes of cancer deaths in Korea and Japan, and IARC/WHO has classified H. pylori as class one carcinogen of gastric cancer. Despite the decreasing prevalence of H. pylori infection, the total number of gastric cancer in Korea has continuously increased from 2006 to 2011. Nevertheless, the 5 year survival rate of gastric cancer patients significantly increased from 42.8% in 1993 to 67% in 2010. This increase in survival rate seems to be mainly due to early detection of gastric cancer and endoscopic mucosal dissection treatment. Based on these findings, the prevalence of peptic ulcer is expected to decrease even more with H. pylori eradication therapy and NSAID will become the main cause of peptic ulcer. Although the prevalence of gastric cancer has not changed along with decreased the prevalence of H. pylori, gastric cancer is expected to decrease in the long run with the help of eradication therapy and endoscopic treatment of precancerous lesions.
Anti-Bacterial Agents/therapeutic use
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects
;
Gastrointestinal Diseases/complications/*epidemiology
;
Helicobacter Infections/complications/drug therapy/epidemiology
;
Humans
;
Lymphoma, B-Cell, Marginal Zone/epidemiology
;
Peptic Ulcer/epidemiology/etiology
;
Prevalence
;
Stomach Neoplasms/etiology/mortality/pathology